Invivyd Inc Ordinary Shares IVVD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IVVD is a good fit for your portfolio.
News
-
Invivyd Sees Covid-19 Prevention Treatment Revenue of Up to $200 Million This Year
-
Thinking about buying stock in Intellicheck, Vanda Pharmaceuticals, Dave Inc, Invivyd, or Dream Finders Homes?
-
Invivyd Shares Give Back Some Gains After Surge From FDA Emergency Approval
-
Invivyd Gets FDA Emergency Use Approval to Prevent Covid-19 in Immunocompromised Adolescents, Adults
Trading Information
- Previous Close Price
- $2.14
- Day Range
- $2.10–2.21
- 52-Week Range
- $1.00–5.10
- Bid/Ask
- $2.10 / $2.11
- Market Cap
- $250.36 Mil
- Volume/Avg
- 52,863 / 746,274
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- < 0.01%
Company Profile
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 95
- Website
- https://www.invivyd.com
Comparables
Valuation
|
Metric
|
IVVD
|
ALVR
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.33 | 0.63 | 5.69 |
Price/Sales | — | — | 23.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
IVVD
ALVR
ACLX
Financial Strength
|
Metric
|
IVVD
|
ALVR
|
ACLX
|
|---|---|---|---|
Quick Ratio | 4.01 | 6.49 | 5.94 |
Current Ratio | 4.47 | 6.61 | 6.06 |
Interest Coverage | — | — | −23.39 |
Quick Ratio
IVVD
ALVR
ACLX
Profitability
|
Metric
|
IVVD
|
ALVR
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −56.33% | −52.75% | −6.26% |
Return on Equity (Normalized) | −63.02% | −66.34% | −12.08% |
Return on Invested Capital (Normalized) | −62.36% | −59.54% | −13.11% |
Return on Assets
IVVD
ALVR
ACLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gchqdjjk | Ygzs | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kggcmtlb | Mdxfjvh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lmrljvjy | Bzrylmk | $97.8 Bil | |
MRNA
| Moderna Inc | Mxpwyqmk | Ytt | $41.3 Bil | |
ARGX
| argenx SE ADR | Lyckgrgsv | Prh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ljhncfqrl | Pjp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mvnwrpfzb | Ntrpwyf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vktdpbmr | Vkccb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wxlhywhgc | Dlnsgk | $12.5 Bil | |
INCY
| Incyte Corp | Pjhxvghl | Fspmjp | $11.6 Bil |